Close

Drug price hikes can damage company reputations: White House

Go back to Drug price hikes can damage company reputations: White House

Mylan (MYL) Affirms Favorable USPTO Ruling to Invalidate Two Teva Patents Covering Copaxone

August 24, 2016 4:48 PM EDT

Mylan N.V. (NASDAQ, TASE: MYL) announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of Mylan in its inter partes review (IPR) proceeding and found all claims of two related Copaxone® 40 mg/mL patents to be unpatentable. The U.S. Patent Nos. are 8,232,250 and 8,399,413, which are owned by Yeda Research & Development Co., Ltd. and licensed to... More